Plant Name: Boswellia carterii
Taxonomic Information:
Plant ID: NPO15315
Plant Latin Name: Boswellia carterii
Taxonomy Genus: Boswellia
Taxonomy Family: Burseraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| MAPK1; CDK8; CSNK2A1; | |
| AR; NR3C2; PGR; NR3C1; | |
| ESR2; | |
| NR1H4; | |
| HSD11B1; HSD17B1; | |
| HIF1A; | |
| LMNA; SERPINA6; FABP4; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 5.136E-14 | 1.118E-09 | AR, ESR2, HSD17B1, NR1H4, NR3C1, NR3C2, PGR, SERPINA6 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 6.062E-11 | 4.400E-07 | AR, ESR2, NR1H4, NR3C1, NR3C2, PGR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.192E-10 | 1.738E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.143E-10 | 2.240E-06 | AR, CDK8, ESR2, NR1H4, NR3C1, NR3C2, PGR |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.779E-09 | 4.843E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.018E-09 | 1.511E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.332E-08 | 1.813E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.123E-07 | 2.958E-04 | AR, ESR2, NR1H4, PGR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.612E-07 | 3.277E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.092E-06 | 8.496E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 2.055E-06 | 1.443E-03 | AR, ESR2, NR3C1, PGR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.571E-06 | 1.697E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 2.901E-06 | 1.776E-03 | ACHE, AR, HSD17B1, NR3C1 |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 4.066E-06 | 2.393E-03 | AR, PGR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.151E-06 | 3.440E-03 | CSNK2A1, HIF1A, NR3C1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.126E-06 | 3.686E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.614E-06 | 3.752E-03 | CYP19A1, CYP1A1, CYP2C19 |
| MF | GO:0140110; transcription regulator activity | GO:0001077; transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding | 1.485E-05 | 5.548E-03 | AR, HIF1A, NR1H4, NR3C1, PGR |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 1.589E-05 | 5.673E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, HIF1A, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.028E-05 | 7.011E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0019222; regulation of metabolic process | 2.743E-05 | 9.190E-03 | ACHE, AR, CDK8, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR2, FABP4, HIF1A, MAPK1, NR1H4, NR3C1, NR3C2, PGR, SERPINA6, THPO, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.429E-11 | 5.182E-09 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.955E-07 | 1.152E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.251E-08 | 1.902E-06 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.372E-06 | 4.014E-05 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.277E-05 | 2.987E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.674E-04 | 7.165E-03 | AR, MAPK1, PGR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.040E-04 | 8.424E-03 | CYP1A2, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; SERPINA6; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; NR3C2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2; |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; SERPINA6; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; CSNK2A1; ACHE; HIF1A; NR3C1; MAPK1; NR3C2; PGR; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NR3C1; NR3C2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; NR3C1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | NR3C2; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | NR3C2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
